Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,701.00
Ask: 1,701.50
Change: 32.00 (1.91%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,718.50
Low: 1,673.00
Prev. Close: 1,673.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Women struggling to crack glass ceiling in top UK companies-report

Wed, 26th Mar 2014 15:17

* Women now hold fifth of FTSE 100 board positions

* Few women on executive committees with only 4 CEOs

* Campaigners push for voluntary change, not quotas (Adds new quotes, numbers, after report launch)

By Belinda Goldsmith

LONDON, March 26 (Reuters) - More women are sitting on theboards of Britain's blue-chip companies but the glass ceilingis yet to crack, with most top jobs still held by men andcompanies needing to do more to promote women, a governmentreport said on Wednesday.

The third annual progress report found women now occupy afifth, or 20.7 percent, of positions in FTSE 100 companies, upfrom 12.5 percent in 2011, within striking distance of a targetfor women to account for one quarter of board seats by 2015.

But campaigners admitted there was still a long way to go aswomen only account for 6.9 percent of senior executive roles inthe FTSE 100 where there are only four women chief executives.

Two companies in the FTSE 100, commodities trader GlencoreXstrata and miner Antofagasta, still haveall-male boards - although they told Reuters they are seekingfemale directors - and 48 FTSE 250 companies have all-maleboards.

Former trade minister Mervyn Davies, leader of thegovernment initiative since 2011, said the figures showed avoluntary drive to boost women around the boardroom table wasworking and ruled out the need for mandatory quotas such asthose introduced in France, Italy, Spain and the Netherlands andplanned for Germany.

He said the key to lasting improvement was encouragingcompanies to drive change within, not legislation or governmentintervention that critics argue can lead to tokenism and "trophydirectors".

"This is about changing the culture of corporate Britain,and using a stick is not the best way to do that," Davies toldReuters after launching the latest report in London.

"Everyone now sees that (having more women on boards) isgreat business sense so the debate is now moving from theboardroom to executive committees."

BUSINESS CREDIBILITY

He said Britain was leading the way at driving corporatechange on a voluntary basis rather than with quotas which arenow being mulled in the European Union.

But he said companies whether public or private had to stepup to the mark and he has written to all companies in the FTSE350 urging them to find ways to boost female representation.

"Failure would again raise the unwelcome proposal ofcompulsory measures. British business credibility is at stakeand we need to redouble our efforts," Davies said.

Minister for Women Maria Miller said companies needed to behonest that the culture in Britain was not neutral and it wasstill "white, male and heterosexual".

The only FTSE 100 female CEOs are Moya Greene at Royal Mail, Carolyn McCall at easyJet, Angela Ahrendts atBurberry and Alison Cooper at Imperial Tobacco.

Capita and Diageo had the highest proportionof women among FTSE 100 boards at 44 percent, followed by RoyalMail, Unilever, and GlaxoSmithKline.

Miller said corporate change was needed to address genderimbalance as well as the pay gap between men and women and ruleson executive pay.

"Women don't need special treatment. They just need an equalplaying field," she said.

With the spotlight on promoting women, several British banksreleased targets on gender balance in their annual results forthe first time this year.

HSBC aims to have women in 25 percent of seniorroles by 2014/15, up from 22.7 percent; Lloyds has atarget of 40 percent by 2020 compared to 28 percent now; andBarclays is eyeing 26 percent by 2018, up 5 points.

Davies, the former chief executive of Standard Chartered, said it was "inconceivable in this day and age" tohave an all-male board or executive committee.

"A company that does not get the mood of society on thisissue actually deserves to go out of business," he said. (Additional reporting by Steve Slater, Editing by AlisonWilliams)

More News
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.